ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Soligenix Inc

Soligenix Inc (SNGX)

0.60
-0.0071
(-1.17%)
Closed March 29 04:00PM
0.60
0.00
(0.00%)
After Hours: 05:45PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.60
Bid
0.6001
Ask
0.65
Volume
137,612
0.5924 Day's Range 0.61
0.38 52 Week Range 4.20
Market Cap
Previous Close
0.6071
Open
0.593
Last Trade
8
@
0.6001
Last Trade Time
Financial Volume
$ 82,574
VWAP
0.600046
Average Volume (3m)
309,442
Shares Outstanding
10,378,238
Dividend Yield
-
PE Ratio
-0.45
Earnings Per Share (EPS)
-1.33
Revenue
949k
Net Profit
-13.8M

About Soligenix Inc

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Heal... Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19). Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Soligenix Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SNGX. The last closing price for Soligenix was $0.61. Over the last year, Soligenix shares have traded in a share price range of $ 0.38 to $ 4.20.

Soligenix currently has 10,378,238 shares outstanding. The market capitalization of Soligenix is $6.23 million. Soligenix has a price to earnings ratio (PE ratio) of -0.45.

SNGX Latest News

Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results

Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results PR Newswire PRINCETON, N.J., March 15, 2024 PRINCETON, N.J., March 15, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq:...

Soligenix Announces Formation of Behçet's Disease Medical Advisory Board

Soligenix Announces Formation of Behçet's Disease Medical Advisory Board PR Newswire PRINCETON, N.J., Feb. 8, 2024 Phase 2a clinical study of SGX945 in Behçet's Disease initiating in...

Soligenix to Present at The Microcap Conference

Soligenix to Present at The Microcap Conference PR Newswire PRINCETON, N.J., Jan. 25, 2024 PRINCETON, N.J., Jan. 25, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the...

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease PR Newswire PRINCETON, N.J., Jan. 8, 2024 PRINCETON, N.J., Jan. 8, 2024...

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis PR Newswire PRINCETON, N.J., Jan. 4, 2024 Clinical Success...

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses PR Newswire PRINCETON, N.J., Jan. 2, 2024...

Form 8-K - Current report

0000812796falseDE00008127962023-12-212023-12-21​​UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0462-7.149489322190.64620.660.57616490.609139CS
4-0.13-17.80821917810.730.8250.571064550.70681469CS
12-0.3499-36.83545636380.94990.980.55553094420.82978724CS
260.064312.00298674630.535720.3815571280.89756786CS
52-1.28-68.0851063831.884.20.3810432681.08667883CS
156-22.65-97.419354838723.2524.30.386822038.01372945CS
260-13.05-95.604395604413.6555.20.3882154917.68161681CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

SNGX Discussion

View Posts
fung_derf fung_derf 1 month ago
OK, well good on you for saying so. Now, why are we feeling a $27k investment is going to influence this sucker at all?
👍️0
masterofdisaster masterofdisaster 1 month ago
Yeah ok. That was a squeeze play and I got it wrong.
👍️0
fung_derf fung_derf 1 month ago
ehhhh, not so much....this was it's top of the market at the time. Within a month the stock was at .63....I believe you called me "salty" when I spoke out against your recommendation.

masterofdisaster

Re: None

Monday, August 07, 2023 11:19:15 AM

Post#
10993
of 11238
Buying at $2.75
👍️0
masterofdisaster masterofdisaster 1 month ago
It went up and then cratered
👍️0
fung_derf fung_derf 1 month ago
I think you said the same thing right before Rite Aid cratered.
👍️0
masterofdisaster masterofdisaster 1 month ago
Someone just bought 38,000 shares. Something big is happening here.
👍️0
bigfart bigfart 3 months ago
There must be potential here a lot of buying going on
👍️0
fung_derf fung_derf 3 months ago
Maybe I lied to myself and will buy some today. Geez I HATE penny stocks!
👍️0
fung_derf fung_derf 3 months ago
Hmmmmm
👍️0
elks elks 3 months ago
Fast tracked. See if it pops
👍️0
hogg hogg 3 months ago
Or maybe this morning.
👍️0
bigfart bigfart 3 months ago
Next PR maybe this week
👍️0
TommyBoyTrader9460 TommyBoyTrader9460 3 months ago
$SNGX
https://x.com/hannahadad8890/status/1742250748237189139?s=61
🤡 1
CELTICAPPLE CELTICAPPLE 3 months ago
Wow this is beyond huge. Sky's the limit imho.
👍️0
TruckingAngler TruckingAngler 3 months ago
Yes. Let’s try this again !
👍️0
subslover subslover 3 months ago
NEWS
Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses
Single-vial thermostabilized bivalent vaccine demonstrates simultaneous protection against two lethal viruses

PRINCETON, N.J., Jan. 2, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today a publication describing the preclinical efficacy of a novel, single-vial, bivalent vaccine providing 100% protection against both Sudan ebolavirus (SUDV) and Marburg marburgvirus (MARV) infections. In collaboration with University of Hawai?i at Manoa (UHM), the manuscript entitled "Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection", has been published in Vaccine.


This vaccine candidate has been previously demonstrated to be stable to high temperature storage for at least 2 years at 40 degrees Celsius (104 degrees Fahrenheit). There are currently no approved vaccines or therapeutics for either SUDV or MARV infections. Vaccines are available for Zaire ebolavirus (EBOV) infections but they provide no protection against SUDV or MARV infection. The published paper describes the potency of the bivalent formulation against both viruses, demonstrating 100% protection in the most rigorous non-human primate challenge models.

"Filoviruses such as Zaire ebolavirus, Sudan ebolavirus and Marburg marburgvirus are some of the most lethal viruses known, and they are endemic in areas of the world where the power supply and distribution network can be uncertain. A thermostabilized vaccine in a single vial format would significantly enhance any public health response to a new outbreak, at its source," stated Axel Lehrer, PhD, Associate Professor, Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, UHM. "Our work to date has demonstrated the feasibility of rapid and efficient manufacturing, as well as the ability to thermostabilize multiple antigens that can then be stored for extended times at temperatures exceeding 100 degrees Fahrenheit. The use of a bivalent vaccine has the potential to both prevent future infections with these pathogens and potentially mitigate future outbreak events, potentially using an accelerated dosing regimen."

"Our combined vaccine platform includes 3 major components: a robust protein manufacturing process that has been demonstrated on multiple protein antigens, a novel nano-emulsion adjuvant which induces broad immunity and a formulation procedure which enables thermostabilization of the combination of adjuvant and antigens in a single vial," stated Oreola Donini, PhD, Senior Vice President and Chief Scientific Officer of Soligenix. "Elements of this vaccine platform have been utilized in our ricin toxin, filovirus and COVID-19 vaccine candidates, indicating its broad applicability. The ability to package the vaccine candidates in a single vial further adds to their developability, whether as a multivalent or individual monovalent vaccine, particularly against Marburg marburgvirus and Sudan ebolavirus where there are currently no available vaccines."

Under the Company's Public Health Solutions business segment, ongoing collaborations with Dr. Lehrer have demonstrated the feasibility of developing thermally-stable subunit protein vaccine formulations for filoviruses. The thermostabilized filovirus vaccine program is continuing to advance with the support of a National Institute of Health (NIH) grant R01-AI132323 (awarded to UHM) and a Small Business Innovation Research grant (#1R44AI157593-01; awarded to Soligenix, Inc.). Work to date has demonstrated the compatibility of lyophilizing both antigen and adjuvant in the same vial, with reconstitution with sterile water for injection immediately prior to use. This simple delivery format, as well as the compatibility with ambient storage, enables vaccines that significantly reduce the logistical hurdles that have been required for addressing the current pandemic or deployment of other Ebola virus vaccines in recent outbreaks in Central and West Africa.

About Filovirus Infection

Ebola Virus Disease is caused by one of six species of Ebolavirus, four of which are known to cause disease in humans, including its best-known member, Zaire ebolavirus (Ebola virus), with Sudan ebolavirus being the second-most common cause of human infection in this genus. All species of ebolavirus belong to the Filoviridae family, a family that further contains the equally human pathogenic Marburg virus. Filoviruses are believed to be harbored in various animal species in Africa, particularly bats, although the specific reservoir host for many of these viruses is still unknown. There have been several known Ebola and Marburg Virus Disease outbreaks since 1967, with the largest outbreak starting in 2014 in Western Africa that involved over 26,000 confirmed/probable/suspected cases with an estimated death toll of more than 11,000 people according to the Centers for Disease Control and Prevention (CDC). These numbers also include some cases of virus introduction and limited spread in Europe and the United States. In 2022 and 2023 several SUDV and MARV outbreaks were observed in continental Africa.

Transmission of filoviruses requires direct contact with bodily fluids from an infected person or contact with infected animals. The mortality rates following filovirus infections are extremely high, and, in the absence of wide availability of effective therapeutics, are affected by the quality of supportive care available with a focus on early initiation of treatment. Resolution of the disease largely depends on the patient's own immune system. There are limited treatment options for Ebola Virus Disease and no available treatments for Sudan Virus or Marburg Virus Disease, although steady progress has also been made in development of immunotherapeutics for filoviruses beyond Zaire ebolavirus. There are approved vaccines for Ebola virus (Zaire ebolavirus), requiring stringent ultra-low cold-chain storage, but no efficacious vaccines yet available for Marburg virus (Marburg marburgvirus) or Sudan virus (Sudan ebolavirus
👍️0
TruckingAngler TruckingAngler 3 months ago
Cramer had Schaber on the show!
👍️0
fung_derf fung_derf 3 months ago
What's funny is, this was a strong Jim Cramer pick....well maybe not funny
👍️0
ice_n_ak ice_n_ak 3 months ago
SNGX. There are no fond memories here. A most horrible investment. A most horrible management. A perfect place to lose money.
Once I thought there was potential here 15 years ago so I invested. What a mistake.
Look at my old posts here to take one down memory lane.
Schaber, you're a crook.
👍️0
TruckingAngler TruckingAngler 3 months ago
Nice work Schaber. Sub 50cent for Christmas.
Lying thief
👍️0
bigfart bigfart 4 months ago
Only one PR by the company itself so far the rest are just mentions of the company
👍️0
fung_derf fung_derf 4 months ago
It appears, the second one did no good.
I guess I'm glad I sold some yesterday after all. I could buy some back much cheaper this morning (I think), but not putting any more money here.
👍️0
bigfart bigfart 4 months ago
You're right usually two PRS in one day
👍️0
TruckingAngler TruckingAngler 4 months ago
SNGX always 2x PRs: 12/01/203: "December 01 2023 - 07:30AM PR Newswire
"HyBryte™ has potential to address a critical gap in treatment of early-stage CTCL

PRINCETON, N.J., Dec. 1, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that an article describing the potential use of HyBryte™ in the treatment of cutaneous T-cell lymphoma (CTCL) has been published in Frontiers in Drug Discovery. The mini-review summarizes findings about the use, mechanism and effectiveness of HyBryte™ in the treatment of CTCL with a particular emphasis on the ability of HyBryte™ to address the unmet medical need in patients with early-stage disease.

"With its chronic course and major impact on patient quality of life, CTCL is an orphan disease in urgent need of additional treatment options that are well-tolerated and safe over the long term," stated Brian Poligone, MD, PhD, Director of the Rochester Skin Lymphoma Medical Group, Fairport, NY. "Clinical studies with HyBryte™ have demonstrated its safety and effectiveness, with broad applicability across different lesion types, different skin tones and different disease stages. I know I can speak for my colleagues that have been involved with these studies when I say that the data generated to date has been extremely compelling."

"In treating CTCL, which is a chronic cancer with no cure, long-term safety is a strong driver of treatment choice. Most current treatment options for CTCL are associated with significant safety concerns, including black-box warnings. HyBryte™ treatment has demonstrated strong and rapid efficacy with a very benign safety profile," stated Richard Straube, MD, Senior Vice President and Chief Medical Officer of Soligenix. "Studies to date have indicated a substantial increase in efficacy with longer treatment with similar performance against both patch and plaque lesions. These results are derived from one of the largest studies ever conducted in CTCL and we believe HyBryte™ will be of significant benefit to patients living with this difficult disease."
👍️0
81vette 81vette 4 months ago
12 halts so far,the sma200 has climbed to 1.11 now for support from here,in other words,ave number of ppl who bought in last 200 days are at break even and profit taking should end if news is hopeful enough and if new ppl start buying it will go up now,most tickers don’t exceed the first run up tho because of new profit takers/flippers
👍️0
TruckingAngler TruckingAngler 4 months ago
Yeah I'm around $7 cost-basis as wouldn't throw any more at it...
(because of r/s)
GLTA
👍️0
fung_derf fung_derf 4 months ago
Guess I shouldn't have posted my sell price. I did get rid of some of it.
👍️0
fung_derf fung_derf 4 months ago
Figures. They shut it down right at my cost basis. Dang it!
Does this re-open at $2.50 or .53?

What the heck?? I mention $1.93 on here and suddenly a ton of dumping at $1.93.
👍️0
fung_derf fung_derf 4 months ago
OK, I guess it is halted. Now showing 0X0 for price
👍️0
fung_derf fung_derf 4 months ago
I don't see a halt.
The stock typically trades under 300k shares per day. Today so far its at 37.5 MILLION!
👍️0
Michael TRed Michael TRed 4 months ago
Going to 4$ today. Buckle up
👍️0
81vette 81vette 4 months ago
Nice move today,dang halts,can’t sell,ZERO BORROW,42%fee is promising,profit taking now,sma200 is .80 support bounce
👍️0
fung_derf fung_derf 4 months ago
The cost basis on most of my shares is $1.93. I'm hoping to dump when it gets there.
Admittedly I don't have a full grasp on approval for small pharma companies (most still seem worthless). I don't understand how this news means a whole lot to the company as, it's not a phase III approval, but apparently someone does. And they've been loading up all morning.
I don't own enough of this to care much. Stupidly, I bought into it based on Jim Cramer back in November 2020.
I am always on here telling people not to throw out money on stupid stock plays. Occasionally I do it myself and almost without fail, I am reminded not to do it again.
👍️0
TruckingAngler TruckingAngler 4 months ago
Please do the after lunch BIG run !
GLTA
👍️0
fung_derf fung_derf 4 months ago
The moment market makers realized this is for realz!
Geez, I'll be curious to see if all those shares picked up first thing this morning at .56 get dumped later today.

11/30/23 09:51:15 AM D O 2 0.9800 I
11/30/23 09:51:15 AM D O 600 0.9800
11/30/23 09:51:15 AM D O 160 1.0000
11/30/23 09:51:15 AM P 50 1.0000 I
11/30/23 09:51:15 AM D O 941 1.0000
11/30/23 09:51:15 AM P 10 1.0000 I
11/30/23 09:51:15 AM P 46 1.0000 I
11/30/23 09:51:15 AM P 70 1.0000 I
11/30/23 09:51:15 AM P 50 1.0000 I
11/30/23 09:51:15 AM P 1 1.0000 I
11/30/23 09:51:15 AM P 82 1.0000 I
11/30/23 09:51:15 AM D O 100 0.9900
11/30/23 09:51:15 AM O 0.9800 O 1.0000 28 X 465 BBO
11/30/23 09:51:15 AM P 200 0.9800 Y F
11/30/23 09:51:15 AM P 100 0.9800 Y F
11/30/23 09:51:15 AM O 100 0.9800 Y F
11/30/23 09:51:15 AM O 0.9800 O 1.0000 27 X 465 BBO
11/30/23 09:51:15 AM P 200 0.9800 Y F
11/30/23 09:51:15 AM O 37 0.9800 Y F I
👍️0
fung_derf fung_derf 4 months ago
Trading a MASSIVE amount of shares today. This may be real. There has been no pre-loading for a pump and dump.
👍️0
fung_derf fung_derf 4 months ago
Not sure I trust any of it but....

Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease
PR Newswire7:30 AM (UTC-05:00) Eastern Time (US & Canada) Nov 30, 2023


Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease

PR Newswire

PRINCETON, N.J., Nov. 30, 2023


Pipeline Expansion of Novel Innate Defense Regulator Technology

PRINCETON, N.J., Nov. 30, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 2a clinical trial entitled, "Pilot Study of SGX945 (Dusquetide) in the Treatment of Aphthous Ulcers in Behçet's Disease." The study is designed to evaluate the safety and efficacy of SGX945 (dusquetide) and is expected to begin patient enrollment in the second half of 2024.




"We are pleased to have received FDA clearance on our SGX945 Phase 2 pilot trial in aphthous ulcers of Behçet's disease," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. "Our previous studies with dusquetide in oral mucositis have clearly validated the biologic activity in aphthous ulcers induced by chemotherapy and radiation. Given the role of the innate immune system in ulcers associated with Behçet's Disease, and the unmet medical need particularly for more severe ulcers such as genital and leg ulcers, we believe that dusquetide may offer significant relief to patients. We are excited to expand dusquetide's development into different innate immune-related inflammatory conditions such as Behçet's disease, as a component of our long-term strategy to enhance the value of this unique compound. Behçet's disease is an unmet medical need, with up to 18,000 people in the U.S., 80,000 in Europe, 350,000 people in Turkey and as many as 1 million people worldwide affected by this incurable disease. Given our promising results with aphthous ulcers in oral mucositis, we are hopeful dusquetide will have a role to play in helping underserved patients suffering from this difficult to treat and chronic disease."

Under this IND, the pilot clinical trial of SGX945 will be an open-label study that will enroll approximately 25 patients age 18 years or older with mild to moderate Behçet's disease active oral and/or genital ulcers. Patients will receive SGX945 as a twice weekly 4-minute intravenous (IV) infusion for 4 weeks. Efficacy endpoints will include the extent of lesion clearance, timeline to lesion clearance, and patient reported quality of life indices.

About Dusquetide

Dusquetide (the active ingredient in SGX945 and SGX942 in development for oral mucositis) is an innate defense regulator (IDR), a new class of short, synthetic peptides. It has a novel mechanism of action whereby it modulates the body's reaction to both injury and infection towards an anti-inflammatory, anti-infective, and tissue healing response. IDRs have no direct antibiotic activity but, by modulating the host's innate immune system responses, increase survival after infections caused by a broad range of bacterial Gram-negative and Gram-positive pathogens. It also accelerates resolution of tissue damage following exposure to a variety of agents including bacterial pathogens, trauma, and chemo- and/or radiation therapy. Preclinical efficacy and safety have been demonstrated in numerous animal disease models including mucositis, colitis, macrophage activation syndrome (MAS) as well as bacterial infections, including melioidosis. In addition, potential anti-tumor activity has been demonstrated in multiple in vitro and in vivo xenograft studies.

Dusquetide has demonstrated safety and tolerability in a Phase 1 clinical study in 84 healthy human volunteers. In Phase 2 and 3 clinical studies with SGX942 in over 350 subjects with oral mucositis due to chemoradiation therapy for head and neck cancer, positive efficacy results were demonstrated, including potential long-term ancillary benefits.

Soligenix has a strong intellectual property position in the IDR technology platform, including composition of matter for dusquetide and related analogs. Dusquetide was developed pursuant to discoveries made by Professors B. Brett Finlay, PhD and Robert Hancock, PhD of the University of British Columbia, Canada.

About Behçet's Disease

Behçet's Disease (BD) is commonly known as an inflammatory disorder of the blood vessels (vasculitis). Often first diagnosed in young adults, it's effects and severity will wax and wane over time. Major signs and symptoms usually include mouth sores (approximately 95% of patients), skin rashes and lesions (approximately 50% of patients), genital sores (approximately 50% of patients), leg ulcers (approximately 40% of patients) and eye inflammation (approximately 15% of patients). It is a painful disease, directly impacting the patient's quality of life and ability to productively engage in life activities, including work.

BD is thought to be an auto-immune disease with both genetic and environmental factors. It is most common along the "Silk Road" in the Middle East and East Asia, including Turkey, Iran, Japan and China. There are approximately 18,000 known cases of BD in the U.S. and 80,000 in Europe. There are as many as 1,000,000 people worldwide living with BD.

There is no cure for BD, rather treatments are prescribed to manage symptoms. Treatments may include both maintenance therapies and those specifically addressing flares (e.g., mouth ulcers, genital ulcers and leg ulcers). Corticosteroids are generally applied topically to sores and as eyedrops and may also be given systemically to reduce inflammation. Although used frequently, they have limited efficacy over the long-term and have significant side effects that become more concerning with more chronic use. Genital ulcers are often associated with significant genital scarring while leg ulcers can result in a post-thrombotic syndrome. Other treatments for BD flares involve suppressing the immune system with drugs (e.g., cyclosporine or cyclophosphamide). These drugs come with a higher risk of infection, liver and kidney problems, low blood counts and high blood pressure. Finally, anti-inflammatory drugs are also used, including anti-TNF medications. The only approved drug in BD is apremilast, which is used as a maintenance therapy to prevent formation of oral ulcers. Unfortunately, apremilast is associated with both high cost and side effects including diarrhea, nausea, upper respiratory tract infection and headache.

About Soligenix, Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval is being sought and commercialization activities for this product candidate are being advanced initially in the U.S. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (SGX945) in Behçet's Disease. The Company also is developing proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation such as pediatric Crohn's disease (SGX203).

Our Public Health Solutions business segment includes active development programs for RiVax®, our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).

For further information regarding Soligenix, Inc., please visit the Company's website at https://www.soligeni... and follow us on LinkedIn and Twitter at @Soligenix_Inc.

This press release may contain forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations and clinical trial enrollment. Statements that are not historical facts, such as "anticipates," "estimates," "believes," "hopes," "intends," "plans," "expects," "goal," "may," "suggest," "will," "potential," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements, and include the expected amount and use of proceeds from the offering and the expected closing date of the offering. Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing therapeutics and vaccines against bioterror threats, conducting preclinical and clinical trials of therapeutics and vaccines, obtaining regulatory approvals and manufacturing therapeutics and vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program. In addition, there can be no assurance as to the timing or success of any of its clinical/preclinical trials. Despite the statistically significant result achieved in the HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma, there can be no assurance that a marketing authorization from the FDA or EMA will be successful. Notwithstanding the result in the HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma and the Phase 2a clinical trial of SGX302 for the treatment of psoriasis, there can be no assurance as to the timing or success of the clinical trials of SGX302 for the treatment of psoriasis. Despite the positive efficacy results demonstrated in the Phase 2 and 3 clinical studies of SGX942 for the treatment of oral mucositis due to chemoradiation therapy for head and neck cancer, there can be no assurance as to the timing or success of the clinical trials of SGX945 for the treatment of Behçet's Disease. Further, there can be no assurance that RiVax® will qualify for a biodefense Priority Review Voucher (PRV) or that the prior sales of PRVs will be indicative of any potential sales price for a PRV for RiVax®. Also, no assurance can be provided that the Company will receive or continue to receive non-dilutive government funding from grants and contracts that have been or may be awarded or for which the Company will apply in the future. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission (the "SEC"), including, but not limited to, the Company's preliminary prospectus (Registration No. 333-271049) filed with the SEC on May 4, 2023, and Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

SOURCE SOLIGENIX, INC.

Copyright (c) 2023 PR Newswire Association,LLC. All Rights Reserved.
👍️0
TruckingAngler TruckingAngler 4 months ago
SNGX 11/30 confirmation news the real deal?
Or another run up to dilute, r/s, and fail another 2-3 years?
One can only hope..
GLTA

“7:30a ET 11/30/2023 - PR Newswire
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Beh?et's Disease”
👍️0
TruckingAngler TruckingAngler 5 months ago
I saw no mention of r/s.
Surprisingly
👍️0
81vette 81vette 5 months ago
Read the details of annual meeting,see what is on vote agenda,usually reverse split or other bad dilution when meeting
👍️0
TruckingAngler TruckingAngler 5 months ago
SNGX low volume sell off? WTH?
👍️0
81vette 81vette 7 months ago
No insider dumping,they loading for some reason? Big Accumulation today
👍️0
81vette 81vette 7 months ago
Trading natural today,no dilution,accumulation last 5 days
👍️0
81vette 81vette 7 months ago
3Xs ave vol,2Xs buy vol,bids/demand growing
👍️0
Monksdream Monksdream 7 months ago
The biotech sector is draconian
95 per cent losers
5 per cent long term winners
Crap shoot
👍️ 1
TruckingAngler TruckingAngler 7 months ago
Nice work Schaber. Penny for your thoughts.
SNGX now penny stock pre split…
👍️0
Monksdream Monksdream 7 months ago
SNGX new 52 week low
👍️0
Monksdream Monksdream 7 months ago
SNGX new 52 week low
👍️0
TruckingAngler TruckingAngler 8 months ago
Seemed bit of interest pops this 9m float fast after hours…
Can only hope for good news next week…
GLTA
👍️0
Monksdream Monksdream 8 months ago
SNGX new 52 week low
👍️0

Your Recent History

Delayed Upgrade Clock